Page last updated: 2024-12-07

n-acetyltyramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetyltyramine (NAT) is a naturally occurring trace amine found in various organisms, including humans. It is a derivative of the neurotransmitter tyramine and is synthesized by the enzymatic acetylation of tyramine. NAT has been implicated in a variety of physiological functions, including neurotransmission, mood regulation, and appetite control. Research suggests that NAT may act as a neuromodulator, influencing the activity of other neurotransmitters. NAT has also been associated with various conditions, such as Parkinson's disease, Alzheimer's disease, and depression. It is believed that NAT may play a role in the pathogenesis of these disorders by modulating neurotransmitter systems. NAT is studied to understand its role in neurotransmission, its potential therapeutic applications in neurological and psychiatric disorders, and its contribution to the development of various conditions.'

N-acetyltyramine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-acetyltyramine : A member of the class of tyramines that is tyramine in which one of the hydrogens of the amino group is replaced by an acetyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID121051
CHEMBL ID152117
CHEBI ID125610
SCHEMBL ID734658
MeSH IDM0153815

Synonyms (51)

Synonym
MEGXM0_000183
acetamide, n-(2-(4-hydroxyphenyl)ethyl)-
n-acetyl tyramine
n-(2-(4-hydroxyphenyl)ethyl)acetamide
brn 2096467
n-(p-hydroxyphenethyl)acetamide
acetamide, n-[2-(4-hydroxyphenyl)ethyl]-
n-acetyltyramine
ACON1_000453
smr000440653
MLS000877027
NCGC00169064-01
n-(4-hydroxyphenethyl)acetamide
n-[2-(4-hydroxyphenyl)ethyl]acetamide
1202-66-0
CHEBI:125610
bdbm50136842
n-[2-(4-hydroxy-phenyl)-ethyl]-acetamide
n-[2-(4-hydroxyphenyl)ethylacetamide
gnf-pf-5230 ,
CHEMBL152117 ,
BRD-K65981456-001-01-5
FT-0693682
acetamide, n-(p-hydroxyphenethyl)-
bzb50e9qvy ,
unii-bzb50e9qvy
4-13-00-01794 (beilstein handbook reference)
HMS2269F23
AKOS010245572
tyramine, n-acetyl
SCHEMBL734658
4-(2-acetamino-ethyl)-phenol
n-(4-hydroxyphenylethyl)acetamide
n-[2-(4-hydroxyphenyl)ethyl]acetamide #
n-(p-hydroxyphenethyl) acetamide
Q27216226
DTXSID60152731
mfcd01670887
n-(4-hydroxyphenethyl)acetamide, 95%
HY-120504
CS-0078197
n-acetyltyramine, >=95% (lc/ms-elsd)
ZB0388
DS-3568
SY103177
acetyltyramine, n-
AMY5135
Y10620
A892285
n-acetyl-tyramine
BAA20266

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
Aspergillus metaboliteAny fungal metabolite produced during a metabolic reaction in the mould, Aspergillus.
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
quorum sensing inhibitorAny compound that interferes with bacterial communication (quorum sensing, QS).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
tyraminesAralkylamino compounds which contain a tyramine skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
eyes absent homolog 2 isoform aHomo sapiens (human)Potency89.12511.199814.641950.1187AID488837
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Sus scrofa (pig)IC50 (µMol)160.00000.01500.61352.5000AID34780
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1437557Antibacterial activity against Staphylococcus aureus ATCC 6538 up to 60 uM after 16 to 48 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Spoxazomicin D and Oxachelin C, Potent Neuroprotective Carboxamides from the Appalachian Coal Fire-Associated Isolate Streptomyces sp. RM-14-6.
AID34780Inhibition of pig kidney aldose reductase (ALR2)2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Rational design of an indolebutanoic acid derivative as a novel aldose reductase inhibitor based on docking and 3D QSAR studies of phenethylamine derivatives.
AID1437567Cytotoxicity against human A549 cells assessed as decrease in cell viability up to 20 uM after 48 hrs by resazurin assay2017Journal of natural products, 01-27, Volume: 80, Issue:1
Spoxazomicin D and Oxachelin C, Potent Neuroprotective Carboxamides from the Appalachian Coal Fire-Associated Isolate Streptomyces sp. RM-14-6.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID378803Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 as parasite DNA microfluorimetric assay2006Journal of natural products, Oct, Volume: 69, Issue:10
Antiplasmodial metabolites isolated from the marine octocoral Muricea austera.
AID1437559Antibacterial activity against Escherichia coli NRRL B-3708 up to 60 uM after 16 to 48 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Spoxazomicin D and Oxachelin C, Potent Neuroprotective Carboxamides from the Appalachian Coal Fire-Associated Isolate Streptomyces sp. RM-14-6.
AID1437561Antifungal activity against Saccharomyces cerevisiae ATCC 204508 up to 60 uM after 16 to 48 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Spoxazomicin D and Oxachelin C, Potent Neuroprotective Carboxamides from the Appalachian Coal Fire-Associated Isolate Streptomyces sp. RM-14-6.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1437560Antibacterial activity against Salmonella enterica ATCC 10708 up to 60 uM after 16 to 48 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Spoxazomicin D and Oxachelin C, Potent Neuroprotective Carboxamides from the Appalachian Coal Fire-Associated Isolate Streptomyces sp. RM-14-6.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1437558Antibacterial activity against Micrococcus luteus NRRL B-287 up to 60 uM after 16 to 48 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
Spoxazomicin D and Oxachelin C, Potent Neuroprotective Carboxamides from the Appalachian Coal Fire-Associated Isolate Streptomyces sp. RM-14-6.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (20.00)18.7374
1990's1 (4.00)18.2507
2000's5 (20.00)29.6817
2010's11 (44.00)24.3611
2020's3 (12.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.59 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]